semaglutide / tirzepatide and key differences, weight loss results (2026) Weight loss: Semaglutide or tirzepatide,

Safety follow-up cannot end when the acute effects do

If nausea is persistent, your prescriber may recommend slowing the dose escalation schedule rather than stopping treatment altogether

Published 2022 Mar 15

This weight loss has given me a lot more energy, rejuvenating my ability to enjoy sports and activities with a renewed zest

Eligible Medicare members can now access select FDA-approved GLP-1 medications including Wegovy and Zepbound through the Medicare GLP-1 Bridge Program, running July 1, 2026 through December 31, 2027

Additionally, molecular signals such as pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) can cross into the circulation, potentially impacting both the microbiota and CNS function